Wang X, Shi J, Zhu HJ (2023) <br />Targeted Absolute Protein Quantification Using SILAC Internal Standard and Full-Length Protein Calibrators (TAQSI)<br /><i>Methods Mol Biol</i> <b>2603</b>: 269<br /><br />Her L, Shi J, Wang X, He B, Smith L, Jiang H, Zhu HJ (2022) <br />Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms<br /><i>Proteomics</i> <br /><br />Xiao J, Shi J, Thompson BR, Smith DE, Zhang T, Zhu HJ (2022) <br />Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex<br /><i>J Pharm Sci</i> <br /><br />Collins JM, Lu R, Wang X, Zhu HJ, Wang D (2021) <br />Transcriptional regulation of carboxylesterase 1 (CES1) in human liver: role of the nuclear receptor NR1H3 (LXRalpha) and its splice isoforms<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <br /><br />Her LH, Wang X, Shi J, Choi HJ, Jung SM, Smith LS, Wu AH, Bleske BE, Zhu HJ (2021) <br />Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects<br /><i>British Journal of Clinical Pharmacology</i> <br /><br />Li J, Liu S, Shi J, Zhu HJ (2021) <br />Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection<br /><i>Pharmaceutics</i> <b>13</b>: <br /><br />Li J, Shi J, Xiao J, Tran L, Wang X, Zhu HJ (2021) <br />Contributions of Cathepsin A and Carboxylesterase 1 to the hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <br /><br />Shi J, Xiao J, Wang X, Jung SM, Bleske BE, Markowitz JS, Patrick KS, Zhu HJ (2021) <br />Plasma carboxylesterase 1 predicts methylphenidate exposure: a proof-of-concept study using plasma protein biomarker for hepatic drug metabolism<br /><i>Clinical Pharmacology & Therapeutics</i> <br /><br />Wang X, Her L, Xiao J, Shi J, Wu AH, Bleske BE, Zhu HJ (2021) <br />Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers<br /><i>Clin Transl Sci</i> <br /><br />Her L, Zhu HJ (2020) <br />Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>48</b>: 230<br /><br />Shenoy VM, Thompson BR, Shi J, Zhu HJ, Smith DE, Amidon GL (2020) <br />Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme<br /><i>Mol Pharm</i> <b>17</b>: 1706<br /><br />Shi J, Xiao J, Li J, Wang X, Her L, Sorensen MJ, Zhu HJ (2020) <br />FRACPRED-2D-PRM: A fraction prediction algorithm-assisted two-dimensional liquid chromatography-based parallel reaction monitoring-mass spectrometry approach for measuring low-abundance proteins in human plasma<br /><i>Proteomics</i> <br /><br />He B, Shi J, Wang X, Jiang H, Zhu HJ (2019) <br />Label-free absolute protein quantification with data-independent acquisition<br /><i>J Proteomics</i> <b>200</b>: 51<br /><br />Hu Y, Epling D, Shi J, Song F, Tsume Y, Zhu HJ, Amidon GL, Smith DE (2018) <br />Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice<br /><i>Biochemical Pharmacology</i> <b>156</b>: 147<br /><br />Wang X, Shi J, Zhu HJ (2018) <br />Functional study of Carboxylesterase 1 protein isoforms<br /><i>Proteomics</i> <br /><br />Wang X, Rida N, Shi J, Wu AH, Bleske BE, Zhu HJ (2017) <br />A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>45</b>: 1149<br /><br />Zhu HJ, Patrick KS, Straughn AB, Reeves OT, 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS (2017) <br />Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers<br /><i>J Clin Psychopharmacol</i> <b>37</b>: 419<br /><br />Sanford JC, Wang X, Shi J, Barrie ES, Wang D, Zhu HJ, Sadee W (2016) <br />Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus<br /><i>Pharmacogenet Genomics</i> <b>26</b>: 197<br /><br />Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ (2016) <br />Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>44</b>: 554<br /><br />Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ (2016) <br />Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender<br /><i>Biochemical Pharmacology</i> <b>119</b>: 76<br /><br />Shi J, Wang X, Eyler RF, Liang Y, Liu L, Mueller BA, Zhu HJ (2016) <br />Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms<br /><i>Basic Clin Pharmacol Toxicol</i> <b>119</b>: 555<br /><br />Wang X, Liang Y, Liu L, Shi J, Zhu HJ (2016) <br />Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI)<br /><i>Rapid Commun Mass Spectrom</i> <b>30</b>: 553<br /><br />Wang X, Wang G, Shi J, Aa JY, Comas R, Liang Y, Zhu HJ (2016) <br />CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors<br /><i>Pharmacogenomics J</i> <b>16</b>: 220<br /><br />Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS (2016) <br />CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril<br /><i>European Journal of Clinical Pharmacology</i> <b>72</b>: 681<br /><br />Wang X, Zhu HJ, Markowitz JS (2015) <br />Carboxylesterase 1-Mediated Drug-Drug Interactions between Clopidogrel and Simvastatin<br /><i>Biol Pharm Bull</i> <b>38</b>: 292<br /><br />Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, Markowitz JS, Hansen PR (2014) <br />Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study<br /><i>Clinical Pharmacology & Therapeutics</i> <b>96</b>: 713<br /><br />Markowitz JS, Zhu HJ, Patrick KS (2013) <br />Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability<br /><i>J Child Adolesc Psychopharmacol</i> <b>23</b>: 648<br /><br />Zhu HJ, Markowitz JS (2013) <br />Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation<br /><i>European Journal of Clinical Pharmacology</i> <b>69</b>: 733<br /><br />Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013) <br />Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>344</b>: 665<br /><br />Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS (2012) <br />Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions<br /><i>Pharm Res</i> <b>29</b>: 972<br /><br />Zhu HJ, Brinda B, Froehlich TE, Markowitz JS (2012) <br />A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants<br /><i>Pharmacogenet Genomics</i> <b>22</b>: 215<br /><br />Zhu HJ, Patrick KS, Markowitz JS (2011) <br />Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: Application to human ethanol interactions<br /><i>Journal of Chromatography B Analyt Technol Biomed Life Sciences</i> <b>879</b>: 783<br /><br />Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS (2010) <br />Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions<br /><i>Toxicology</i> <b>270</b>: 59<br /><br />Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS (2009) <br />Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril<br /><i>Biochemical Pharmacology</i> <b>77</b>: 1266<br /><br />Zhu HJ, Markowitz JS (2009) <br />Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>37</b>: 264<br /><br />Zhu HJ, Appel DI, Jiang Y, Markowitz JS (2009) <br />Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>37</b>: 1819<br /><br />Jiang MY, Wang F, Yang XL, Fang LZ, Dong ZJ, Zhu HJ, Liu JK (2008) <br />Derivatives of vibralactone from cultures of the basidiomycete Boreostereum vibrans<br /><i>Chem Pharm Bull (Tokyo)</i> <b>56</b>: 1286<br /><br />LeVasseur NL, Zhu HJ, Markowitz JS, DeVane CL, Patrick KS (2008) <br />Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping<br /><i>Journal of Chromatography B Analyt Technol Biomed Life Sciences</i> <b>862</b>: 140<br /><br />Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, Cong RH, Zhu HJ, Wang B (2008) <br />Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population<br /><i>J Lipid Res</i> <b>49</b>: 369<br /><br />Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008) <br />Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis<br /><i>American Journal of Human Genetics</i> <b>82</b>: 1241<br /><br />Liu DZ, Wang F, Liao TG, Tang JG, Steglich W, Zhu HJ, Liu JK (2006) <br />Vibralactone: a lipase inhibitor with an unusual fused beta-lactone produced by cultures of the basidiomycete Boreostereum vibrans<br /><i>Org Lett</i> <b>8</b>: 5749<br /><br />